News

Referred to as TIMES (Trials of IMeglimin for Efficacy and Safety), the Imeglimin Phase 3 program in Japan includes three pivotal trials to evaluate Imeglimin’s efficacy and safety

The Phase 1/2 dose-rising trial will evaluate the safety and preliminary efficacy of NanoDoce for patients with high-risk non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer

Evenity is a bone-building humanized monoclonal antibody developed to inhibit the activity of sclerostin. It is claimed to be the only bone builder that simultaneously increases bone formation

The collaboration will leverage both companies’ scientific and technological expertise and will build on Alnylam’s recent preclinical data showing potent and highly durable delivery of RNAi therapeutics to

Delivering an inhaled Dry Powder formulation of Aspirin directly into the deep sites of the lung is a novel new approach to lung cancer treatment. This new treatment

The approval has been granted for a complete, once-daily, single-tablet regimen of dolutegravir (DTG) 50mg and lamivudine (3TC) 300mg to treat HIV-1 infection in adults with no antiretroviral

Under the terms of the partnership, South Korea-based Celltrion will undertake manufacturing and supply of four recombinant antibodies to iProgen. Among the four antibodies, two will be targeting

INFUGEM, the first chemotherapy product that comes in a premixed, ready-to-infuse formulation, was approved by the U.S. Food and Drug Administration (FDA) in July 2018 in combination with

The material collaboration terms for patisiran, vutrisiran, and fitusiran, as previously announced, will continue unchanged. “Our landmark 2014 rare disease alliance with Sanofi resulted in the advancement of